(Q48009346)

7 February 2018

title

Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease (English)

1 reference

7 February 2018

main subject

Pseudomonas aeruginosa

0 references

author name string

Stephan Sorichter

1

1 reference

7 February 2018

Ulrich Baumann

2

1 reference

7 February 2018

Astrid Baumgart

3

1 reference

7 February 2018

Stephan Walterspacher

4

1 reference

7 February 2018

Bernd-Ulrich von Specht

5

1 reference

7 February 2018

language of work or name

English

0 references

publication date

13 March 2009

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

27

1 reference

7 February 2018

issue

21

1 reference

7 February 2018

page(s)

2755-2759

1 reference

7 February 2018

Lower respiratory tract infections in chronic obstructive pulmonary disease outpatients with tracheostomy and persistent colonization by P. aeruginosa.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

A 7-year study of severe hospital-acquired pneumonia requiring ICU admission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Regional specialization in the mucosal immune system: what happens in the microcompartments?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Role of secretory antibodies in the defence against infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Recognition of host immune activation by Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Ventilator-associated pneumonia: Incidence, risk factors, outcome, and microbiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.010

10.1016/J.VACCINE.2009.03.010

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018